Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FES | P07332 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 10/20 | 0.54 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.52 |
| ▸ | TTK | P33981 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | INSR | P06213 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985900 | 0.91 | FES (0.74) | FESFLT3IGF1RTTKALK | |
| SCHEMBL22985878 | 0.88 | FES (0.61) | FESFLT3IGF1RZAP70TTK | |
| SCHEMBL3959279 | 0.87 | FES (0.84) | FESFLT3IGF1RZAP70TTK | |
| SCHEMBL22985890 | 0.86 | FES (0.60) | FESFLT3IGF1RZAP70TTK | |
| SCHEMBL22985873 | 0.86 | FES (0.62) | FESFLT3IGF1RZAP70TTK | |
| SCHEMBL22985897 | 0.84 | FES (0.64) | FESFLT3IGF1RTTKALK | |
| SCHEMBL22985860 | 0.79 | LRRK2 (0.53) | FESFLT3 | |
| SCHEMBL3954048 | 0.78 | FES (1.00) | FESFLT3IGF1RZAP70TTK | |
| SCHEMBL22985876 | 0.77 | FES (0.49) | FESFLT3IGF1RZAP70ALK | |
| SCHEMBL3954360 | 0.77 | FES (0.86) | FESFLT3IGF1RZAP70TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |